ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 1682

Significance of Anti-Topoisomerase I Antibodies in Routine Clinical Testing

Anne E Tebo1, Robert L. Schmidt2 and Tracy M. Frech3, 1University of Utah, Salt Lake City, UT, 2Pathology, University of Utah, Salt Lake City, UT, 3Division of Rheumatology, University of Utah, Salt Lake City, UT

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: laboratory tests, lung and scleroderma

Session Information

Date: Monday, November 6, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The 2013 classification criteria for systemic sclerosis (SSc) provide 3 points (towards a 9 point diagnosis) for patients who have an anti-topoisomerase I (anti-Scl-70) antibody.  From a clinical practice standpoint, in the absence of other stigmata of SSc, the significance of the presence of an anti-Scl-70 antibody result remains unclear. The purpose of this project was to determine the clinical relevance of anti-Scl-70 antibodies detected by multiplex testing for patients receiving routine clinical evaluation at our institution. 

Methods: Results for patients positive for anti-Scl-70 antibodies (cut-off: >41 AU/mL positive) at the University of Utah over a period of 8 years were retrospectively reviewed. All patients with a positive anti-Scl-70 antibody had a manual chart review for other SSc classification criteria information.

Results: There were 3331 unique patient samples evaluated during the investigation period, 51 (1.53%) were positive for anti-Scl-70 antibodies with 5 patients lost to follow-up. Of the available anti-Scl-70 antibody-positive patients (n=46), 17 (37%) met the diagnostic criteria for SSc, 11 (23.9%) were diagnosed with other types of lung disease [sarcoidosis, pulmonary embolism, empyema, and constrictive bronchiolitis], the remaining patients had immune-mediated diseases [n=12] or no reported clinical diagnosis [n=6]. All anti-Scl-70 antibody patients with SSc were also positive for antinuclear antibodies (ANA) compared to those without disease (100% vs. 46.4%, p<0.0001). The median level of anti-Scl-70 antibodies was significantly higher in patients with SSc compared to those without disease [158 AU/mL vs. 60 AU/mL, p<0.0001, Figure 1). Using logistic regression, an estimated probability of 1 for SSc was attained at anti-Scl-70 antibody level of approximately 200 AU/mL (Figure 2).

Conclusion: In this retrospective study, a positive ANA test and significantly elevated titers (>5x cut-off) of anti-Scl-70 may be predictive of SSc. The role of underlying lung pathology on the pathogenesis of developing a low titer anti-Scl-70 antibody without an ANA may warrant further study.


Disclosure: A. E. Tebo, None; R. L. Schmidt, None; T. M. Frech, None.

To cite this abstract in AMA style:

Tebo AE, Schmidt RL, Frech TM. Significance of Anti-Topoisomerase I Antibodies in Routine Clinical Testing [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/significance-of-anti-topoisomerase-i-antibodies-in-routine-clinical-testing/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/significance-of-anti-topoisomerase-i-antibodies-in-routine-clinical-testing/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology